Testing extra scans and data to guide ovarian cancer treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial collects information from people with suspected ovarian cancer and uses it to improve diagnosis and help predict which treatments may work. It may also look for targeted options, based on scan and medical data results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re being evaluated at Turku University Hospital for suspected ovarian cancer
- You can understand the study and agree to sign a written consent form
- You are 18 years old or older
- You are well enough to receive active treatment like surgery and/or chemotherapy
- You are able to have an FDG PET/CT scan as part of the study (and your blood sugar control is adequate if you have diabetes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
This study looks at “biomarkers,” meaning measurable signals in blood and tumor tissue, in people with advanced ovarian-type cancers. The goal is to understand these markers and how they relate to the cancer, which may help guide future care.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This study looks at how medical images relate to genetic patterns in high-grade serous ovarian cancer. It may help find better ways to diagnose and treat this specific type of ovarian cancer.
This pilot study uses a special PET/CT scan (with a radioactive tracer) to help doctors better “stage” high-grade epithelial ovarian cancer—especially when it’s advanced. The goal is to see whether the scan can improve planning for treatment like surgery or chemotherapy first.
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
Hear when a new High Grade Ovarian Serous Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.